Knight Therapeutics (TSE:GUD) had its stock price target increased to $12.50 by TD Securities in a report issued Friday March 17, 2017. The updated target suggests a potential upside of 0.22% from the company's previous stock price.

On 03/15/2017, National Bank Financial released a statement for Knight Therapeutics (TSE:GUD) increased the target price from $11.00 to $11.75. At the time, this indicated a possible upside of 0.12%.

Just yesterday Knight Therapeutics (TSE:GUD) traded -1.64% lower at $10.22. Knight Therapeutics’s 50-day moving average is $10.57 and its 200-day moving average is $9.89. The last closing price is up 3.18% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same time. 570,616 shares of Knight Therapeutics exchanged hands, up from an avg. volume of 175,317

See Chart Below

Knight Therapeutics has 52 week low of $7.20 and a 52 week high of $11.03 with a PE ratio of 71.83 and has a total market value of $0.

A total of 10 analysts have reported on the stock. 0 firms rating the stock a strong buy, 0 brokers rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $8.12.

Brief Synopsis About Knight Therapeutics (TSE:GUD)

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.

The post Knight Therapeutics (TSE:GUD) target bumped up to $12.50, issued a report today by TD Securities appeared first on Octafinance.